Investors

Perrigo is uniquely positioned as the only global company with a mix of generic over-the-counter and prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients, delivering value by meeting the growing need for "Quality Affordable Healthcare Products®."

Recast restated historical financial information filed May 25, 2017 can be found here.

Cautionary Note Regarding Certain Previously Reported Financial Results -- Investors and others should not rely on annual or quarterly financial information published for the fiscal years ended June 28, 2014 and June 27, 2015; the transition period from June 28, 2015 to December 31, 2015; and the quarterly periods ended December 28, 2013, March 29, 2014, September 27, 2014, December 27, 2014, March 28, 2015, September 26, 2015, April 2, 2016, July 2, 2016 and October 1, 2016. See the Form 10-K and Q1 2016 Form 10-Q/A, Q2 2016 Form 10-Q/A and Q3 2016 Form 10-Q/A filed on May 22 and 23, 2017.


print email rss
Price Data
NYSEPRGO
Key Contacts
Bradley Joseph
Vice President, Global Investor Relations
269-686-3373
bradley.joseph@perrigo.com
Arthur J. Shannon, Vice President
Global Corporate Affairs and European Investor Relations
(269) 686-1709
ajshannon@perrigo.com